Roche, Dicerna sign $1.67bn deal for HBV infection treatment

This article was originally published here

Under the research collaboration and licensing agreement, the companies will work on the worldwide development and commercialisation of DCR-HBVS, Dicerna’s investigational therapy in phase 1 clinical development for

The post Roche, Dicerna sign $1.67bn deal for HBV infection treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply